Mangaluru: Drunk man misbehaves with woman; gets thrashed by her son

Bengaluru, Apr 13: Eminent scientist and NITI Aayog member V K Saraswat said on Monday the number of COVID- 19 cases is not going to go beyond what's being reported daily in India as he maintained that the country is in the process of flattening the curve.

The former Scientific Adviser to Defence Minister said the coronavirus positive cases have seen a sharper rise in the last four-five days because of increase in the number of testing.

"It's a good sign; all those asymptomatic cases lying hidden they are also coming out," Saraswat told PTI. "We certainly had a catalytic factor which was basically this (Nizamuddin) Markaz problem which has actually created clusters at different places and that has also been one of the factors for the kind of rise that has taken place."

But he said India is in a much better shape compared to other nations in the battle against COVID-19. "I can only say that the rate is not going to go beyond what has been going on now, may be 700 to 800 cases per day. So, we are in the process of flattening the curve."

The government's decision to declare nation-wide lockdown has paid dividends, Saraswat, a former chief of the Defence Research and Development Organisation, said.

Noting that India has seen a series of virus attacks in the last 15-20 years including Chikungunya and Dengue, he said the emphasis now should be on more and more R & D to find vaccines in advance.

Bengaluru, Mar 29: Escoms have been directed neither to penalise its customers nor go for disconnection if one fails to pay the bill. The relief is applicable till June. However, the entire bill will have to be paid at the end of three months.

The revised power tariff, which was to be announced on April 1, has also been deferred.

A similar three-month relief has been given on rentals for APMC and BBMP shops.

New Delhi, Jun 11: The Department of Pharmaceuticals has given its nod for lifting of ban on the export of hydroxychloroquine, Union Minister D V Sadananda Gowda said on Wednesday.

India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could be used to fight COVID-19. On April 4, it completely banned the exports without any exception.

"Department of Pharmaceuticals has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market," the minister of chemicals and fertilisers said in a tweet.

The Directorate General of Foreign Trade (DGFT) has been asked to issue formal notification in this regard, he added.

In another tweet, Gowda said he held discussions with representatives of pharma companies along with some of his ministerial colleagues on the challenges being faced by the industry and on the roadmap to boost exports.

"Had detailed discussion with representatives of pharma companies & association, stakeholder Ministries along with Hon Ministers @piyushGoyal  ji, @HardeepSPuri  ji, & @MansukhMandviya  ji on entire gamut of challenges faced by the industry as well as strategies to boost pharma export," Gowda tweeted.

India exported hydroxychloroquine API (active pharmaceutical ingredient) worth USD 1.22 billion in April-January 2019-20.

During the same period, exports of formulations made from hydroxychloroquine was at USD 5.50 billion.